Additional file 2 of Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

Additional file 2. Characteristics of Included 136 studies

Additional file 1 of Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

Additional file 1. Cochrane Library Search Strategy (May 2021)

Parameter settings based on real methylation datasets.

<p>Parameter settings based on real methylation datasets.</p

(a) Simulated power based on the <i>PTPRD</i> gene. (b) Simulated power based on the <i>MLH1</i> gene.

<p>(a) Simulated power based on the <i>PTPRD</i> gene. (b) Simulated power based on the <i>MLH1</i> gene.</p

CpG set analysis results of DNA methylation datasets from epigenome studies.

<p>CpG set analysis results of DNA methylation datasets from epigenome studies.</p

Empirical Type I error rates based on a real methylation dataset.

<p>Empirical Type I error rates based on a real methylation dataset.</p

Parameter settings of virtual datasets.

<p>Parameter settings of virtual datasets.</p

Empirical Type I error rates at <i>α</i> = 0.05 level under different scenarios.

<p>Empirical Type I error rates at <i>α</i> = 0.05 level under different scenarios.</p

Metabolites associated with PM_2.5 metal welding fume exposure.

*<p>Values presented as mean ± SD (min∼max).</p

Association of PM_2.5 metal welding fume exposure with metabolite pathways.

a<p>Number of biochemical compounds within the same pathway;</p>b<p>Number of biochemical compounds that have the same coefficient direction when regressed by exposure both in Study-2011 and Study-2012;</p>c<p>Number of biochemical compounds with association <i>p<</i>0.05 in combined dataset analyzed by linear mixed model with adjustment of age and medication use;</p>d<p>First principal component (PC₁) was used as response, with PM_2.5 total exposure as predictor in linear regression model or linear mixed-effects model;</p>e<p>Proportion of variance explained by PC₁;</p>f<p>PC₁ was used as response in the linear mixed model with random slope with or without adjustment of age and medication use.</p